

(10) International Publication Number
WO 2017/001354 A1(43) International Publication Date
5 January 2017 (05.01.2017)

(51) International Patent Classification:

C07D 471/04 (2006.01) A61K 31/437 (2006.01)
C07D 487/04 (2006.01) A61P 35/00 (2006.01)
C07D 498/04 (2006.01)

(21) International Application Number:

PCT/EP2016/064899

(22) International Filing Date:

27 June 2016 (27.06.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/185,852 29 June 2015 (29.06.2015) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; 151 85 Södertälje (SE).

(72) Inventors: PIKE, Kurt, Gordon; AstraZeneca, Darwin Building, Cambridge Science Park, Milton Road, Cambridge CB4 0WG (GB). BARLAAM, Bernard, Christophe; AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). HAWKINS, Janet; AstraZeneca, Alderley Park Cheshire, Macclesfield, Cheshire SK10 4TG (GB). DE SAVI, Christopher; AstraZeneca 35 Gatehouse

Drive, Waltham, MA 02451 (US). VASBINDER, Melissa, Marie; AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451 (US). HIRD, Alexander; AstraZeneca 35 Gatehouse Drive, 02451, MA Waltham (US). LAMB, Michelle; AstraZeneca 35 Gatehouse Drive, Waltham, MA 02451 (US).


(74) Agent: REBECCA BARRETT; Astrazeneca Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,

[Continued on next page]

(54) Title: POLYCYCLIC AMIDE DERIVATIVES AS CDK9 INHIBITORS



(57) Abstract: Provided are a series of novel pyridine or pyrimidine derivatives of Formula (I) which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative diseases such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer. A is C(R⁵) or N; R² is H, C₁₋₃alkyl, CN or halogen; R² is optionally substituted 3-7 membered heterocycloalkyl or 3-7 membered cycloalkyl; R⁴ is (A) or (B) wherein X and Y together with the atoms to which they are attached form an optionally substituted, saturated or partially saturated 5 to 7 membered heterocycloalkyl ring which, in addition to the bridge nitrogen, may contain one or two heteroatoms selected from N, O, and S; J is N or CR¹¹; and R¹¹ is H or C₁₋₃alkyl.





TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*